No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 22 of the 34 quarters in the window, leaving 12 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 2564.8x · 10Y median 139.1x · 88th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 35
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:01:16.511Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Dianthus Therapeutics, Inc. (DNTH) stock was $87.31 as of Oct 6, 2026, 10:00 AM EDT, down 0.83% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +150.9% · 3-year avg +94.3%/yr · 5-year avg -5.5%/yr
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function.
Biotechnology · New York, NY
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 5, 2026
30 days away
EPS Estimate
-0.94
Revenue Est.
$443851.00
Last Quarter Results
EPS
$-0.90
vs Estimate
$-0.91
Revenue
$761000.00
vs Estimate
$297182.00
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1DNTH | $4.88B | $87.31 | -0.83% | +150.87% | -5.50% | N/A | N/A |
| 2MIRM | $4.90B | $80.32 | -1.36% | +11.57% | +37.24% | N/A | vs DNTH |
| 3DFTX | $4.79B | $36.10 | -0.37% | +187.00% | +1.43% | N/A | vs DNTH |
| 4BLLN | $4.98B | $108.34 | -0.66% | N/A | N/A | N/A | vs DNTH |
| 5ERAS | $5.05B | $14.55 | -1.15% | +503.05% | -8.34% | N/A | vs DNTH |
| 6LFST | $4.71B | $12.15 | -0.57% | +120.94% | -1.46% | N/A | vs DNTH |
forward FY estimate
N/A
Consensus Rating
Based on 15 analysts
Average Price Target
$140.80
+61.3% upside
Low
$122.00
Current
$87.31
High
$200.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-1.05 | $-0.94 | $-0.87 | 8 |
| Quarter ending Dec 2026 | $-1.21 | $-1.07 | $-0.98 | 8 |
| Quarter ending Mar 2027 | $-1.49 | $-1.11 | $-0.53 | 3 |
| Quarter ending Jun 2027 | $-1.51 | $-1.12 | $-0.54 | 4 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-4.08 | $-3.79 | $-3.64 | 11 |
| FY 2027 | $-5.57 | $-4.57 | $-3.93 | 11 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $317036.00 | $443851.00 | $481895.00 | 9 |
| Quarter ending Dec 2026 | $215172.00 | $358620.00 | $454252.00 | 9 |
| Quarter ending Mar 2027 | $263794.00 | $439657.00 | $556898.00 | 7 |
| Quarter ending Jun 2027 | $249091.00 | $415152.00 | $525859.00 | 4 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $1.09M | $1.88M | $2.49M | 11 |
| FY 2027 | $1.23M | $2.03M | $3.16M | 10 |
